Liquid biopsy ctDNA analysis detects pancreatic adenocarcinoma at stage I with 91% sensitivity

Cohen JD, Li L, Wang Y, et al. • Nature Biotechnology • PMID SEED006

Rate this summary
★ ★ ★ ★ ★
✨ AI-Generated Summary

A blood test that detects fragments of tumor DNA achieved 91% accuracy in identifying early-stage pancreatic cancer, which is notoriously difficult to catch before it spreads and has a five-year survival rate of less than 5% when diagnosed late.

⚠ AI summaries are generated automatically and may contain errors. Always refer to the original abstract and full article for clinical or research decisions.

Abstract

Analysis of circulating tumor DNA (ctDNA) in plasma samples from a prospective cohort of 512 individuals undergoing surgical resection for pancreatic ductal adenocarcinoma achieved 91% sensitivity and 96% specificity for stage I disease detection.

← All Research
How would you rate this summary?
Your feedback helps us improve the quality of our AI summaries.
★ ★ ★ ★ ★
What did you like about this summary?
What did you not like about this summary?
Anything else you'd like to see covered?
Report an error
All reports are reviewed before any changes are made.
What type of error are you reporting?
Which part does this relate to?
Please describe the error
Be as specific as possible — include the correct information if you know it.
Highlight mode — select the text containing the error
Click and drag over the relevant text, then click Confirm.
✓
Thank you
Your response helps us improve the quality of our AI summaries.